Statistics from Altmetric.com
In the new World Health Organisation (WHO) classification of haematological malignancies, immunophenotypical analysis plays an important role in the subclassification of lymphomas.1 In the past decade, many new antibodies have become available that can be used on routinely fixed, paraffin wax embedded tissue sections. At present, it is possible to make a correct subclassification of T cell lymphomas in most cases using a relatively restricted set of markers in combination with clinical presentation. However, in some cases it may be difficult to differentiate a benign T cell response from a malignant T cell proliferation. In these cases, clonality analysis based on the presence of monoclonal T cell receptor rearrangements is indicated.
In table 1 the most discriminating markers are depicted in relation to the different entities, as recognised by the WHO classification.
CD3, CD4, CD8, CD56, and CD30 all give a predominantly membranous staining. However, in extranodal NK/T cell lymphoma, nasal type, CD3 staining is usually cytoplasmic. In other entities cytoplasmic CD3 is unusual.
Staining with granzyme B, perforin, and TIA-1 always gives characteristic granular cytoplasmic staining reflecting expression in the cytotoxic granules.2
Terminal deoxynucleotidyl transferase staining is strictly nuclear.
The presence of the Epstein Barr virus (EBV) in the tumour cells can only be determined reliably using RNA in situ hybridisation detecting the abundantly transcribed EBV encoded RNAs (EBER). Expression of EBV encoded latent membrane 1 is frequently undetectable in EBER positive T cell lymphomas.